Cargando…
ERCC1 Expression Analysis to Guide Therapy in Non-Small Cell Lung Cancer
Worldwide, lung cancer accounts for approximately 1 million deaths each year, making it the most common cause of cancer-related mortality. Non-small cell lung cancer (NSCLC) accounts for approximately 85% of lung cancer cases and is often associated with a relatively poor prognosis. The majority of...
Autores principales: | Allingham-Hawkins, Diane, Lea, Andrew, Levine, Susan |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2998231/ https://www.ncbi.nlm.nih.gov/pubmed/21152077 http://dx.doi.org/10.1371/currents.RRN1202 |
Ejemplares similares
-
DecisionDx-GBM Gene Expression Assay for Prognostic Testing in Glioblastoma Multiform
por: Allingham-Hawkins, Diane, et al.
Publicado: (2010) -
BRAF p.Val600Glu (V600E) Testing for Assessment of Treatment Options in Metastatic Colorectal Cancer
por: Lea, Andrew, et al.
Publicado: (2010) -
KIF6 p.Trp719Arg Testing to Assess Risk of Coronary Artery Disease and/or Statin Response
por: Allingham-Hawkins, Diane, et al.
Publicado: (2010) -
Use of Epidermal Growth Factor Receptor Mutation Analysis in Patients with Advanced Non-Small-Cell Lung Cancer to Determine Erlotinib Use as First-Line Therapy
por: Ishibe, Naoko, et al.
Publicado: (2011) -
Testing of VKORC1 and CYP2C9 alleles to guide warfarin dosing: Test Category: Pharmacogenomic (Treatment)
por: Grossniklaus, Daurice
Publicado: (2010)